A Bayesian decision approach for sample size determination in phase II trials

DOI10.1111/J.0006-341X.2001.00309.XMaRDI QIDQ3078735zbMATH OpenOpenAlexWikidataFDO

Authors Denis Heng-Yan Leung, You-Gan Wang

Publication date 1 March 2011

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.0006-341x.2001.00309.x

zbMATH Keywords

sequential designsample sizegittins indexgain function

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05) Bayesian problems; characterization of Bayes procedures (62C10)

Recommendations

• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• Approximately optimal designs for phase II clinical studies
• A Bayesian Approach to the Design of Phase II Clinical Trials
• Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies
• Bayesian Optimal Design for Phase II Screening Trials

Cites work

• scientific article; zbMATH DE number 194374 (Why is no real title available?)
• An Optimal Design for Screening Trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory

Cited in

(11)

• A Sample-Size-Optimal Bayesian Procedure for Sequential Pharmaceutical Trials
• Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design
• Decision-Theoretic Designs for Phase II Clinical Trials Allowing for Competing Studies
• A Bayesian algorithm for sample size determination for equivalence and non-inferiority test
• Practical Bayesian Guidelines for Phase IIB Clinical Trials
• Approximately optimal designs for phase II clinical studies
• Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed
• A Bayesian Approach to the Design of Phase II Clinical Trials
• Motivating sample sizes in adaptive phase I trials via Bayesian posterior credible intervals
• Sample Size Determination for Phase II Clinical Trials Based on Bayesian Decision Theory
• A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups

This page was built for publication: A Bayesian decision approach for sample size determination in phase II trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3078735)